HMGCR and migraine disorder: Additionally, a separate Mendelian randomization study revealed that genetic indicators for HMG-CoA reductase inhibition are linked to a 36% reduced likelihood of migraines in the FinnGen dataset (95% CI 0.46–0.88) [14].